Partners Capital Investment Group Holdings LLC acquired a new position in Incyte Corporation (NASDAQ:INCY) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,563 shares of the biopharmaceutical company’s stock, valued at approximately $533,000.
A number of other institutional investors also recently added to or reduced their stakes in INCY. Tower Research Capital LLC TRC boosted its position in Incyte by 13.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 108 shares in the last quarter. Seven Eight Capital LP acquired a new position in shares of Incyte during the 2nd quarter worth approximately $129,000. IFP Advisors Inc raised its stake in shares of Incyte by 9.9% during the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 103 shares during the period. Sun Life Financial INC raised its stake in shares of Incyte by 9,069.2% during the 2nd quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock worth $150,000 after buying an additional 1,179 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in shares of Incyte by 130.4% during the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,325 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 750 shares during the period. Institutional investors and hedge funds own 90.86% of the company’s stock.
Incyte Corporation (NASDAQ:INCY) opened at $93.71 on Wednesday. Incyte Corporation has a 52 week low of $93.49 and a 52 week high of $153.15. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81.
Several brokerages have recently weighed in on INCY. BMO Capital Markets reaffirmed an “outperform” rating and set a $163.00 target price (down from $172.00) on shares of Incyte in a research note on Monday, September 11th. Oppenheimer reaffirmed a “hold” rating and set a $135.00 target price on shares of Incyte in a research note on Sunday, September 10th. Goldman Sachs Group began coverage on Incyte in a research note on Friday, October 6th. They set a “buy” rating and a $160.00 target price for the company. ValuEngine downgraded Incyte from a “hold” rating to a “sell” rating in a research note on Wednesday, November 29th. Finally, Evercore ISI began coverage on Incyte in a research note on Wednesday, August 16th. They set an “in-line” rating and a $135.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Incyte currently has a consensus rating of “Buy” and a consensus price target of $145.65.
In related news, President Herve Hoppenot sold 70,502 shares of the stock in a transaction on Monday, September 18th. The stock was sold at an average price of $119.45, for a total value of $8,421,463.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Reid M. Huber sold 696 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $98.01, for a total value of $68,214.96. The disclosure for this sale can be found here. Over the last three months, insiders sold 104,334 shares of company stock valued at $11,992,011. 17.70% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This story was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.com-unik.info/2017/12/06/partners-capital-investment-group-holdings-llc-acquires-new-stake-in-incyte-corporation-incy.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).
What are top analysts saying about Incyte Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Incyte Corporation and related companies.